0000894560 --12-31 false 2021 Q3 0000894560 2021-01-01 2021-09-30 0000894560 2021-09-30 0000894560 2020-06-30 0000894560 2021-11-18 0000894560 2020-12-31 0000894560 2021-07-01 2021-09-30 0000894560 2020-07-01 2020-09-30 0000894560 2020-01-01 2020-09-30 0000894560 us-gaap:CommonStockMember 2020-12-31 0000894560 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000894560 us-gaap:RetainedEarningsMember 2020-12-31 0000894560 2021-01-01 2021-03-31 0000894560 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000894560 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000894560 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000894560 2021-03-31 0000894560 us-gaap:CommonStockMember 2021-03-31 0000894560 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000894560 us-gaap:RetainedEarningsMember 2021-03-31 0000894560 2021-04-01 2021-06-30 0000894560 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000894560 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000894560 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000894560 2021-06-30 0000894560 us-gaap:CommonStockMember 2021-06-30 0000894560 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000894560 us-gaap:RetainedEarningsMember 2021-06-30 0000894560 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000894560 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000894560 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000894560 us-gaap:CommonStockMember 2021-09-30 0000894560 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000894560 us-gaap:RetainedEarningsMember 2021-09-30 0000894560 2019-12-31 0000894560 us-gaap:CommonStockMember 2019-12-31 0000894560 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000894560 us-gaap:RetainedEarningsMember 2019-12-31 0000894560 2020-01-01 2020-03-31 0000894560 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000894560 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000894560 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000894560 2020-03-31 0000894560 us-gaap:CommonStockMember 2020-03-31 0000894560 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000894560 us-gaap:RetainedEarningsMember 2020-03-31 0000894560 2020-04-01 2020-06-30 0000894560 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000894560 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000894560 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000894560 us-gaap:CommonStockMember 2020-06-30 0000894560 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000894560 us-gaap:RetainedEarningsMember 2020-06-30 0000894560 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000894560 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000894560 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000894560 2020-09-30 0000894560 us-gaap:CommonStockMember 2020-09-30 0000894560 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000894560 us-gaap:RetainedEarningsMember 2020-09-30 0000894560 fil:Director1Member 2021-01-01 2021-09-30 0000894560 fil:Director1Member 2020-01-01 2020-09-30 0000894560 fil:Director1Member 2020-12-31 0000894560 fil:Director1Member 2021-09-30 0000894560 fil:NewlyAffiliatedPartyMember 2018-03-08 0000894560 fil:NewlyAffiliatedPartyMember 2021-09-30 0000894560 fil:NewlyAffiliatedPartyMember 2020-12-31 0000894560 fil:SoleOfficerAndDirectorMember 2017-12-12 0000894560 fil:SoleOfficerAndDirectorMember 2020-12-31 2020-12-31 0000894560 fil:SoleOfficerAndDirectorMember 2020-12-31 0000894560 fil:SoleOfficerAndDirectorMember 2021-01-01 2021-09-30 0000894560 fil:SoleOfficerAndDirectorMember 2021-09-30 0000894560 fil:SoleOfficerAndDirectorMember 2020-01-01 2020-09-30 0000894560 fil:PromissoryNote1Member 2016-06-14 0000894560 fil:PromissoryNote1Member 2021-01-01 2021-09-30 0000894560 fil:PromissoryNote1Member 2020-01-01 2020-09-30 0000894560 fil:PromissoryNote1Member 2021-09-30 0000894560 fil:PromissoryNote1Member 2020-12-31 0000894560 fil:PromissoryNote2Member 2018-08-15 0000894560 fil:PromissoryNote2Member 2021-01-01 2021-09-30 0000894560 fil:PromissoryNote2Member 2020-01-01 2020-09-30 0000894560 fil:PromissoryNote2Member 2021-09-30 0000894560 fil:PromissoryNote2Member 2020-12-31 0000894560 fil:PromissoryNote3Member 2018-11-15 0000894560 fil:PromissoryNote3Member 2021-01-01 2021-09-30 0000894560 fil:PromissoryNote3Member 2020-01-01 2020-09-30 0000894560 fil:PromissoryNote3Member 2021-09-30 0000894560 fil:PromissoryNote3Member 2020-12-31 0000894560 fil:PromissoryNote4Member 2018-12-31 0000894560 fil:PromissoryNote4Member 2021-01-01 2021-09-30 0000894560 fil:PromissoryNote4Member 2020-01-01 2020-09-30 0000894560 fil:PromissoryNote4Member 2021-09-30 0000894560 fil:PromissoryNote4Member 2020-12-31 0000894560 fil:PromissoryNote5Member 2019-01-23 0000894560 fil:PromissoryNote5Member 2021-01-01 2021-09-30 0000894560 fil:PromissoryNote5Member 2020-01-01 2020-09-30 0000894560 fil:PromissoryNote5Member 2021-09-30 0000894560 fil:PromissoryNote5Member 2020-12-31 0000894560 fil:PromissoryNote6Member 2020-05-01 0000894560 fil:PromissoryNote6Member 2021-01-01 2021-09-30 0000894560 fil:PromissoryNote6Member 2020-01-01 2020-09-30 0000894560 fil:PromissoryNote6Member 2021-09-30 0000894560 fil:PromissoryNote6Member 2020-12-31 0000894560 fil:ALenderMember 2021-09-30 0000894560 fil:ALenderMember 2021-01-01 2021-09-30 0000894560 fil:ALenderMember 2020-12-31 0000894560 fil:ALenderMember 2020-12-31 2020-12-31 0000894560 fil:ALenderMember 2020-01-01 2020-09-30 0000894560 fil:ALender2Member 2021-09-30 0000894560 fil:ALender2Member 2021-01-01 2021-09-30 0000894560 fil:ALender2Member 2020-12-31 0000894560 fil:ALender2Member 2020-12-31 2020-12-31 0000894560 fil:ALender2Member 2020-01-01 2020-09-30 0000894560 fil:ALender3Member 2021-09-30 0000894560 fil:ALender3Member 2021-01-01 2021-09-30 0000894560 fil:ALender3Member 2020-01-01 2020-09-30 0000894560 fil:ALender3Member 2020-12-31 0000894560 2020-11-02 2020-11-02 0000894560 1990-07-26 2021-09-30 xbrli:pure iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

Form 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2021

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 5(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ______________________________ to ______________________________

 

Commission File Number 33-55254-41

 

BIOETHICS, LTD.
(Exact name of registrant as specified in charter)
NEVADA (NV)	87-0485312
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
1661 Lakeview Circle, Ogden, Utah	84403
(Address of principal executive offices)	(Zip Code)
(801) 399-3632
(Issuer’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act: NONE

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes [X]    No [  ]

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes [X]    No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer[  ]Accelerated filer[  ] 

Non-accelerated filer[X]Smaller reporting company☒ 

Emerging growth company☐ 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   [  ]

---

1

---

 

Indicate by check mark whether the issuer is a shell company (as defined in rule 12b-2 of the Exchange Act).  Yes ☒    No [  ]

 

As of November 18, 2021, the issuer had outstanding 1,135,194 shares of common stock, par value $0.001.

 

---

2

---

BIOETHICS, LTD.

 

FORM 10-Q

 

FOR THE QUARTER ENDED SEPTEMBER 30, 2021

 

 

INDEX

 

PART I   Financial Information

 

Item 1.Condensed Financial Statements (Unaudited)3 

 

Item 2.  Management’s Discussion and Analysis of Financial Condition

 and Results of Operations9 

 

Item 3.  Quantitative and Qualitative Disclosures About Market Risk10 

 

Item 4.  Controls and Procedures10 

 

PART II Other Information

 

Item 1.  Legal Proceedings11 

 

Item 1A.  Risk Factors11 

 

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds11 

 

Item 3.  Defaults Upon Senior Securities11 

 

Item 4.  Mine Safety Disclosures11 

 

Item 5.  Other Information11 

 

Item 6.  Exhibits12 

 

SIGNATURES12 

---

3

---

PART I – FINANCIAL INFORMATION

 

Item 1.Condensed Financial Statements (Unaudited) 

 

 

BIOETHICS, LTD.

 

CONTENTS

 

PAGE 

 

 

—Condensed Unaudited Balance Sheets,  

As of September 30, 2021 and December 31, 20204 

 

 

—Condensed Unaudited Statements of Operations,  

For the three and nine months ended September 30, 2021 and 20205 

 

 

—Condensed Unaudited Statements of Stockholders’ Deficit  

For the three and nine months ended September 30, 2021 and 2020                         6 

 

 

—Condensed Unaudited Statements of Cash Flows,  

For the nine months ended September 30, 2021 and 2020                         7 

 

 

—Notes to Condensed Unaudited Financial Statements for the nine months 

ended September 30, 2021 and 20208 

---

4

---

BIOETHICS, LTD.
Condensed Balance Sheets
(Unaudited)
ASSETS
							September 30,		December 31,
							2021		2020
CURRENT ASSETS
	Cash and cash equivalents						$              554		$              667
		Total Current Assets					554		667
FIXED ASSETS, NET							12		226
		TOTAL ASSETS					$              566		$              893
LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES
	Accounts payable						$         75,929		$         53,943
	Accounts payable - related party						6,000		1,500
	Accrued interest - related parties						39,473		20,561
	Accrued interest						53,574		38,503
	Convertible notes payable, net of unamortized debt discount of $-0- and $2,718, respectively						35,000		32,282
	Notes payable						150,000		150,000
	Notes payable - related parties						203,084		182,834
		Total Current Liabilities					563,060		479,623
		TOTAL LIABILITIES					563,060		479,623
STOCKHOLDERS' DEFICIT
	Preferred stock, $0.01 par value; 25,000,000 shares authorized, -0- shares issued and outstanding						-		-
	Common stock, $0.001 par value; 250,000,000 shares authorized, 1,135,194 shares issued and outstanding						1,135		1,135
	Additional paid-in capital						500,479		500,479
	Accumulated deficit						(1,064,108)		(980,344)
		Total Stockholders' Deficit					(562,494)		(478,730)
		TOTAL LIABILITIES AND STOCKHOLDERS'  DEFICIT					$              566		$              893
The accompanying notes are an integral part of these unaudited condensed financial statements.

---

5

---

BIOETHICS, LTD.
Condensed Statements of Operations
(Unaudited)
					For the Three Months Ended				For the Nine Months Ended
					September 30,				September 30,
					2021		2020		2021		2020
NET REVENUES					$                   -		$                   -		$                   -		$                   -
OPERATING EXPENSES
	General and administrative				14,873		12,922		47,063		55,894
		Total Operating Expenses			14,873		12,922		47,063		55,894
LOSS FROM OPERATIONS					(14,873)		(12,922)		(47,063)		(55,894)
OTHER INCOME (EXPENSES)
	Interest expense				(10,833)		(11,130)		(36,701)		(32,529)
		Total Other Income (Expenses)			(10,833)		(11,130)		(36,701)		(32,529)
NET LOSS BEFORE INCOME TAXES					(25,706)		(24,052)		(83,764)		(88,423)
PROVISION FOR INCOME TAXES					-		-		-		-
NET LOSS					$        (25,706)		$        (24,052)		$        (83,764)		$        (88,423)
BASIC AND DILUTED LOSS PER SHARE					$            (0.02)		$            (0.02)		$            (0.07)		$            (0.08)
WEIGHTED AVERAGE NUMBER OF
SHARES OUTSTANDING					1,135,194		1,135,194		1,135,194		1,135,194
The accompanying notes are an integral part of these unaudited condensed financial statements.

---

6

---

BIOETHICS, LTD.
Condensed Statements of Stockholders' Deficit
(Unaudited)
		Nine Months Ended September 30, 2021
						Additional				Total
		Common Stock				Paid-In		Accumulated		Stockholders'
		Shares		Amount		Capital		Deficit		Deficit
Balance, December 31, 2020		1,135,194		$            1,135		$         500,479		$        (980,344)		$        (478,730)
Net loss for the three months ended
March 31, 2021		-		-		-		(28,175)		(28,175)
Balance, March 31, 2021		1,135,194		1,135		500,479		(1,008,519)		(506,905)
Net loss for the three months ended
June 30, 2021		-		-		-		(29,883)		(29,883)
Balance, June 30, 2021		1,135,194		1,135		500,479		(1,038,402)		(536,788)
Net loss for the three months ended
September 30, 2021		-		-		-		(25,706)		(25,706)
Balance, September 30, 2021		1,135,194		$            1,135		$         500,479		$     (1,064,108)		$        (562,494)
		Nine Months Ended September 30, 2020
						Additional				Total
		Common Stock				Paid-In		Accumulated		Stockholders'
		Shares		Amount		Capital		Deficit		Deficit
Balance, December 31, 2019		1,135,194		$            1,135		$         494,279		$        (861,153)		$        (365,739)
Net loss for the three months ended
March 31, 2020		-		-		-		(36,657)		(36,657)
Balance, March 31, 2020		1,135,194		1,135		494,279		(897,810)		(402,396)
Beneficial conversion feature
on convertible notes payable		-		-		6,200		-		6,200
Net loss for the three months ended
June 30, 2020		-		-		-		(27,714)		(27,714)
Balance, June 30, 2020		1,135,194		1,135		500,479		(925,524)		(423,910)
Net loss for the three months ended
September 30, 2020		-		-		-		(24,052)		(24,052)
Balance, September 30, 2020		1,135,194		$            1,135		$         500,479		$        (949,576)		$        (447,962)
The accompanying notes are an integral part of these unaudited condensed financial statements.

---

7

---

BIOETHICS, LTD.
Condensed Statements of Cash Flows
(Unaudited)
							For the Nine Months Ended
							September 30,
							2021		2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss							$        (83,764)		$        (88,423)
Adjustments to reconcile net loss to net cash
used by operating activities:
		Amortization of debt discount					2,718		5,635
		Depreciation					214		214
Changes in operating assets and liabilities:
		Accounts payable					21,986		11,588
		Accounts payable - related party					4,500		(1,500)
		Accrued interest - related parties					18,912		3,304
		Accrued interest					15,071		13,590
		Net Cash Used by Operating Activities					(20,363)		(55,592)
CASH FLOWS FROM INVESTING ACTIVITIES							-		-
CASH FLOWS FROM FINANCING ACTIVITIES
		Proceeds from convertible notes payable					-		25,000
		Proceeds from notes payable					-		5,000
		Proceeds from notes payable - related parties					20,250		23,900
		Repayment of notes payable - related parties					-		(6,000)
		Net Cash Provided by Financing Activities					20,250		47,900
DECREASE IN CASH AND CASH EQUIVALENTS							(113)		(7,692)
CASH AND CASH EQUIVALENTS AT
BEGINNING OF PERIOD							667		8,761
CASH AND CASH EQUIVALENTS AT
END OF PERIOD							$              554		$           1,069
SUPPLEMENTAL DISCLOSURES:
	Cash paid for interest						$                   -		$         10,000
	Cash paid for income taxes						$                   -		$                   -
	Non-cash investing and financing activities:
		Disposal of fully-depreciated fixed asset					$                   -		$              187
		Beneficial conversion feature on convertible note payable					$                   -		$           6,200
The accompanying notes are an integral part of these unaudited financial statements.

---

8

---

BIOETHICS, LTD.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

NINE MONTHS ENDED SEPTEMBER 30, 2021 and 2020

---

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Organization - Bioethics, Ltd. (“the Company”) was organized under the laws of the State of Nevada on July 26, 1990.  The Company was organized to provide a vehicle for participating in potentially profitable business ventures which may become available through the personal contacts of and at the complete discretion, of the Company’s officers and directors.  The Company has not paid any dividends and any dividends that may be paid in the future will depend upon the financial requirements of the Company and other relevant factors.

 

The accompanying financial statements have been prepared by the Company without audit.  In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows for the nine months ended September 30, 2021 and 2020 have been made.

 

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted.  It is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2020 audited financial statements.  The results of operations for the nine months ended September 30, 2021 are not necessarily indicative of the operating results for the full year.

 

NOTE 2 - RELATED PARTY TRANSACTIONS

 

Management Compensation - During the nine months ended September 30, 2021 and 2020, the Company did not pay any compensation to its officers and directors.

 

Beginning August 2017, the Company entered into an oral agreement to pay the Company’s President $500 per month as payment for use of his personal residence as the Company’s office and mailing address.  The Company has recorded rent expense of $4,500 during each of the nine months ended September 30, 2021 and 2020, which is included in the general and administrative expenses on the statements of operations.  The amount payable at December 31, 2020 was $1,500.  During the nine months ended September 30, 2021, the Company paid $-0-, resulting in $6,000 payable at September 30, 2021.  

 

On March 8, 2018, the Company entered into a promissory note with a newly-affiliated party in the amount of $43,250. The note is payable on demand and carries interest at 10% per annum.  Interest expense for the nine months ended September 30, 2021 and 2020 was $5,662 and $2,597, respectively, resulting in accrued interest of $15,416 and $9,755 at September 30, 2021 and December 31, 2020, respectively.  Principal balance on the note at September 30, 2021 and December 31, 2020 was $43,250.  

 

On December 12, 2017, the Company entered into a promissory note with its President in the amount of $107,000.  On various dates from the origin of the note through December 31, 2020, the officer advanced the Company an additional $53,270, and the Company made payments of $20,686, resulting in the total note principal balance of $139,584 at December 31, 2020.  During the nine months ended September 30, 2021, the Company received an additional $20,250 and paid a total of $-0- of the principal balance resulting in the total note principal balance of $159,834 at September 30, 2021.  The cumulative note balance is uncollateralized, due on demand, and carries interest at 12% per annum.  Interest expense on the note for the nine months ended September 30, 2021 and 2020 was $13,251 and $10,707, respectively, of which the Company repaid $-0- during the nine months ended September 30, 2021, resulting in accrued interest totaling $24,057 and $10,806 at September 30, 2021 and December 31, 2020, respectively.

 

NOTE 3 - NOTES PAYABLE

 

On June 14, 2016, the Company issued a promissory note in the principal amount of $35,000 to an unaffiliated lender. The Note is due on demand at any time after its original maturity date of June 14, 2017, and carries an interest rate of 8% per annum.  Interest expense for the nine months ended September 30, 2021 and 2020 totaled $2,094 and $2,102, respectively, resulting in accrued interest at September 30, 2021 and December 31, 2020 of $14,836 and $12,742, respectively.  Principal balance due on the note at September 30, 2021 and December 31, 2020 was $35,000.

---

9

---

BIOETHICS, LTD.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

NINE MONTHS ENDED SEPTEMBER 30, 2021 and 2020

---

 

On August 15, 2018, the Company issued a promissory note in the principal amount of $10,000 to an unaffiliated lender. The Note was due on November 15, 2018, is currently in default, and carries an interest rate of 12% per annum.  Interest expense for the nine months ended September 30, 2021 and 2020 totaled $897 and $901, respectively, resulting in accrued interest at September 30, 2021 and December 31, 2020 of $3,005 and $2,108, respectively.  Principal balance on the note at September 30, 2021 and December 31, 2020 was $10,000.

 

On November 15, 2018, the Company issued a promissory note in the principal amount of $20,000 to an unaffiliated lender. The Note was due on February 15, 2019, is currently in default, and carries an interest rate of 12% per annum.  Interest expense for the nine months ended September 30, 2021 and 2020 totaled $1,795 and $1,802, respectively, resulting in accrued interest at September 30, 2021 and December 31, 2020 of $6,010 and $4,215, respectively.  Principal balance on the note at September 30, 2021 and December 31, 2020 was $20,000.

 

On December 31, 2018, the Company issued a promissory note in the principal amount of $30,000 to an unaffiliated lender. The Note was due on December 31, 2019, is currently in default, and carries an interest rate of 12% per annum.  Interest expense for the nine months ended September 30, 2021 and 2020 totaled $2,693 and $2,702, respectively, resulting in accrued interest at September 30, 2021 and December 31, 2020 of $9,015 and $6,322, respectively.  Principal balance on the note at September 30, 2021 and December 31, 2020 was $30,000.

 

On January 23, 2019, the Company issued a promissory note in the principal amount of $50,000 to an unaffiliated lender. The Note was due on January 23, 2020, is currently in default, and carries an interest rate of 12% per annum.  Interest expense for the nine months ended September 30, 2021 and 2020 totaled $4,488 and $4,504, respectively, resulting in accrued interest at September 30, 2021 and December 31, 2020 of $15,025 and $10,537, respectively.  Principal balance on the note at September 30, 2021 and December 31, 2020 was $50,000.

 

On May 1, 2020, the Company issued a promissory note in the principal amount of $5,000 to an unaffiliated lender. The Note was due on May 1, 2021 and is now due on demand and carries an interest rate of 12% per annum.  Interest expense for the nine months ended September 30, 2021 and 2020 totaled $449 and $240, respectively, resulting in accrued interest at September 30, 2021 and December 31, 2020 of $840 and $391, respectively.  Principal balance on the note at September 30, 2021 and December 31, 2020  was $5,000.

 

NOTE 4 – CONVERTIBLE NOTE PAYABLE

 

On December 18, 2019, the Company issued a convertible promissory note in the original principal amount of $10,000 to a lender. The Note was due on June 18, 2020, is currently in default, and carries an interest rate of 8% per annum. The Note is due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $2.00 per share.  The Company recognized a beneficial conversion feature and recorded a debt discount in the amount of $4,000, which was amortized over the life of the promissory note.  At September 30, 2021 and December 31, 2020, the unamortized debt discount was $-0-, and the net convertible note balance was $10,000.  The amortization of debt discount was $-0- and $3,716 during the nine months ended September 30, 2021 and 2020, respectively.  Interest expense for the nine months ended September 30, 2021 and 2020 totaled $897 and $901, respectively, resulting in accrued interest at September 30, 2021 and December 31, 2020 of $2,143 and $1,246, respectively. Principal balance on the note at September 30, 2021 and December 31, 2020 was $10,000.

 

On June 9, 2020, the Company issued a convertible promissory note in the original principal amount of $10,000 to a lender. The Note was due on June 9, 2021, is currently in default, and carries an interest rate of 10% per annum. The Note is due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $2.50 per share.  The Company recognized a beneficial conversion feature and recorded a debt discount in the amount of $6,200, which was amortized over the life of the promissory note. At September 30, 2021 and December 31, 2020, the unamortized debt discount was $-0- and $2,718, respectively, and the net convertible note balance was $10,000 and $7,282, respectively.  The amortization of debt discount was $2,718 and $1,919 during the nine months ended September 30, 2021 and 2020, respectively.  Interest expense for the nine months ended September 30, 2021 and 2020 totaled $860 and $248, respectively, resulting in accrued interest at September 30, 2021 and December 31, 2020 of $1,309 and $449.  Principal balance on the note at September 30, 2021 and December 31, 2020 was $10,000.

---

10

---

BIOETHICS, LTD.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

NINE MONTHS ENDED SEPTEMBER 30, 2021 and 2020

---

 

On August 3, 2020, the Company issued a convertible promissory note in the original principal amount of $15,000 to a lender. The Note was due on August 3, 2021, is currently in default, and carries an interest rate of 8% per annum. The Note is due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $7.00 per share.  The Company did not recognize a beneficial conversion feature or debt discount as the conversion price was higher than the market price at the time of issuance of the note.  Interest expense for the nine months ended September 30, 2021 and 2020 totaled $898 and $191, respectively, resulting in accrued interest at September 30, 2021 and December 31, 2020 of $1,391 and $493. Principal balance on the note at September 30, 2021 and December 31, 2020  was $15,000.

 

NOTE 5 – EQUITY TRANSACTIONS

 

The Company is authorized to issue 250,000,000 shares of common stock.  There were no equity transactions during the nine months ended September 30, 2021 or 2020, resulting in 1,135,194 shares of common stock issued and outstanding at September 30, 2021 and December 31, 2020.

 

Effective November 2, 2020, the Company effectuated a 1 share for 10 shares reverse stock split which reduced the issued and outstanding shares of common stock from 11,000,000 shares to 1,135,194 shares.  The accompanying financial statements have been retroactively adjusted to reflect this reverse stock split.

 

NOTE 6 - GOING CONCERN

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern.  However, the Company has incurred losses since its inception totaling $1,064,108 and has no on-going operations.  These factors raise substantial doubt about the ability of the Company to continue as a going concern.  In this regard, management is proposing to raise any necessary additional funds not provided by operations through loans, additional sales of its common stock, or through a possible business combination.  There is no assurance that the Company will be successful in raising this additional capital or in achieving profitable operations.  In addition, the COVID-19 pandemic could have an impact on our ability to obtain financing to fund the operations. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

 

NOTE 7 - LOSS PER SHARE

 

The computation of basic loss per share is based on the weighted average number of shares outstanding during each period.  

 

The following data show the amounts used in computing loss per share for the nine months ended:

 

		September 30, 2021		September 30, 2020
Net loss (numerator)	$	(83,764)	$	(88,423)
Weighted average shares outstanding (denominator)		1,135,194		1,135,194
Basic and fully diluted net loss per share amount	$	(0.07)	$	(0.08)

 

The following data show the amounts used in computing loss per share for the three months ended:

 

		September 30, 2021		September 30, 2020
Net loss (numerator)	$	(25,706)	$	(24,052)
Weighted average shares outstanding (denominator)		1,135,194		1,135,194
Basic and fully diluted net loss per share amount	$	(0.02)	$	(0.02)

---

11

---

BIOETHICS, LTD.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

NINE MONTHS ENDED SEPTEMBER 30, 2021 and 2020

---

 

The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year plus the common stock equivalents as detailed in the following chart.  For the nine months ended September 30, 2021 and 2020, the inclusion of these shares on the statements of operations would have resulted in a weighted average shares fully diluted number that was anti-dilutive, and as such they are excluded.  

 

The following data show the fully diluted shares for the nine months ended September 30, 2021 and 2020:

 

		September 30,
		2021		2020
Basic weighted average shares outstanding		1,135,194		1,135,194
Convertible debt		12,758		11,615
Total		1,147,952		1,146,809

 

The following data show the fully diluted shares for the three months ended September 30, 2021 and 2020:

 

		September 30,
		2021		2020
Basic weighted average shares outstanding		1,135,194		1,135,194
Convertible debt		12,758		11,615
Total		1,147,952		1,146,809

 

NOTE 8 – SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and determined there are no events requiring disclosure.

---

12

---

---

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

You should read the following discussion in conjunction with our financial statements, which are included elsewhere in this report.  The following information contains forward-looking statements. (See “Forward-Looking Statements” below.)

 

FORWARD-LOOKING STATEMENTS

 

This report contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995.  These statements reflect the Company’s views with respect to future events based upon information available to it at this time.  These forward-looking statements are subject to certain uncertainties and other factors that could cause actual results to differ materially from these statements.  The words “anticipates,” “believes,” “estimates,” “expects,” “plans,” “projects,” “targets,” and similar expressions identify forward-looking statements.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, changes in assumptions, future events or otherwise.

 

General

 

The Company is a shell company that conducts no active business operations and is seeking business opportunities for acquisition or participation by the Company.

 

The Report of Independent Registered Public Accounting Firm on the Company’s December 31, 2020 audited financial statements addresses an uncertainty about the Company’s ability to continue as a going concern, indicating that the Company has incurred losses since its inception and has no on-going operations.  The report further indicates that these factors raise substantial doubt about the Company’s ability to continue as a going concern.  At September 30, 2021, the Company had a working capital deficit of $562,506 and an accumulated deficit since inception of $1,064,108. The Company incurred net losses of $83,764 and $88,423 for the nine months ended September 30, 2021 and 2020, respectively.  The Company has not entered into any agreements or arrangements for the provision of additional debt or equity financing and there can be no assurance that it will be able to obtain the additional debt or equity capital required to continue its operations.  

 

The Three and Nine months ended September 30, 2021 compared to September 30, 2020

 

The Company did not conduct any operations during the nine-month periods ended September 30, 2021 or 2020.  At September 30, 2021, the Company had total current assets consisting solely of cash in the amount of $554, compared to $667 at December 31, 2020.  At September 30, 2021, the Company had total current liabilities of $563,060, compared to $479,623 at December 31, 2020.  The Company had a working capital deficit of $562,506 at September 30, 2021 compared to $478,956 at December 31, 2020.

 

The Company did not generate revenues during the nine-month periods ending September 30, 2021 or 2020.  The Company incurred general and administrative expenses of $14,873 during the three months ended September 30, 2021, compared to $12,922 during the three months ended September 30, 2020.  The Company incurred general and administrative expenses of $47,063 during the nine months ended September 30, 2021, compared to $55,894 during the nine months ended September 30, 2020.  Such expenses consist primarily of legal and accounting fees as well as taxes and annual fees required to maintain the Company’s corporate status.   

 

The Company incurred other expenses of $10,833 during the three months ended September 30, 2021 compared to $11,130 during the three months ended September 30, 2020.  The Company incurred other expenses of $36,701 during the nine months ended September 30, 2021 compared to $32,529 during the nine months ended September 30, 2020.  Total other income and expenses consist of interest expense related to the notes payable due from the Company.  

 

The Company incurred a net loss of $25,706 during the three months ended September 30, 2021, compared to a net loss of $24,052 during the three months ended September 30, 2020.  The Company incurred a net loss of $83,764 during the nine months ended September 30, 2021, compared to a net loss of $88,423 during the nine months ended September 30, 2020.

---

13

---

---

The Company has never had substantial ongoing operations. As a result, since its inception on July 26, 1990, the Company had an accumulated deficit of $1,064,108 as of September 30, 2021.

 

Liquidity and Capital Resources

 

Net cash used by operating activities was $20,363 and $55,592 during the nine months ended September 30, 2021 and 2020, respectively.

 

Net cash provided by investing activities was $-0- during both the nine months ended September 30, 2021 and 2020.

 

Net cash provided by financing activities was $20,250 and $47,900 during the nine months ended September 30, 2021 and 2020, respectively.

 

Since the Company does not generate any revenues from operations, it is dependent on sales of securities, loans, or contributions from its stockholders in order to pay its operating costs. In addition, in the event the Company locates a suitable candidate for potential acquisition, the Company will require additional funds to pay the costs of negotiating and completing the acquisition of such candidate.  The Company has not entered into any agreement or arrangement for the provision of any additional funding and no assurances can be given that such funding will be available to the Company on terms acceptable to it or at all.  

 

The Company cannot presently foresee the cash requirements of any business opportunity which may ultimately be acquired by the Company.  However, since it is likely that any business it acquires will be involved in active business operations, the Company anticipates that an acquisition will result in increased cash requirements as well as increases in the number of employees of the Company.

Off-Balance Sheet Arrangements

 

The Company has not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that are material to investors.

Critical Accounting Policies

 

Due to the lack of current operations and limited business activities, the Company does not have any accounting policies that it believes are critical to facilitate an investor’s understanding of the Company’s financial and operating status.

 

Item 3.  Quantitative and Qualitative Disclosures About Market Risk.

 

Not Applicable.  The Company is a “smaller reporting company.”

 

Item 4. Controls and Procedures.

 

Disclosure Controls and Procedures

 

Under the supervision and with the participation of our management, including our Chief Executive Officer/Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (“the Exchange Act”) as of September 30, 2021, the end of the period covered by this report, utilizing the Committee of Sponsoring Organizations of the Treadway Commission’s 2013 update to the Internal Control Integrated Framework.  Based upon that evaluation, our Chief Executive Officer/Chief Financial Officer concluded that our disclosure controls and procedures as of September 30, 2021 were not effective such that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer/Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure.  A

---

14

---

---

controls system cannot provide absolute assurance, however, that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.  

 

Changes in Internal Control over Financial Reporting

 

There was no change in our internal control over financial reporting during the quarter ended September 30, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 

 

Part II---OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

The Company is not a party to any material pending legal proceedings and, to the best of its knowledge; its properties are not the subject of any such proceedings.

 

Item 1A. Risk Factors.

 

Not Applicable.  The Company is a “smaller reporting company.”

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

Item 3. Defaults Upon Senior Securities.

 

Not Applicable.

 

Item 4. Mine Safety Disclosures.

 

Not Applicable.

 

Item 5. Other Information.

 

None.

---

15

---

---

Item 6.Exhibits 

 

The following documents are included as exhibits to this report:

 

(a)Exhibits 

 

Exhibit Number		SEC Reference Number		Title of Document		Location
31.1		31		Section 302 Certification of Chief Executive and Chief Financial Officer		This Filing
32.1		32		Section 1350 Certification of Chief Executive and Chief Financial Officer		This Filing
101.INS**				XBRL Instance Document		This Filing
101.SCH**				XBRL Taxonomy Extension Schema		This Filing
101.CAL**				XBRL Taxonomy Extension Calculation Linkbase		This Filing
101.DEF**				XBRL Taxonomy Extension Definition Linkbase		This Filing
101.LAB**				XBRL Taxonomy Extension Label Linkbase		This Filing
101.PRE**				XBRL Taxonomy Extension Presentation Linkbase		This Filing

 

 

**XBRL information is furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934, and is not subject to liability under those sections, is not part of any registration statement or prospectus to which it relates and is not incorporated or deemed to be incorporated by reference into any registration statement, prospectus or other document.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Bioethics, Ltd.
Date:  November 18, 2021	By /s/ Mark A. Scharmann
	Mark A. Scharmann
	President, Chief Executive Officer and
	Chief Financial Officer
	(Principal Executive and Financial Officer)

---

16